FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

/PRNewswire/ -- Astellas Pharma US, Inc. (President: Mark Reisenauer, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved...

Related Keywords

United States ,Syria ,Aram ,Stevens Johnson ,Antonioc Arrieta ,Mark Reisenauer ,Lynn Fenicchia ,Drug Administration ,Prnewswire Astellas Pharma Us Inc ,Facebook ,Basilea Pharmaceutica International Ltd ,Astellas Pharma Us Inc ,Children Health Of Orange ,Linkedin ,Astellas Pharma Inc ,Pediatric Infectious Disease ,Specialties Business Unit ,Medical Mycology ,Invasive Aspergillosis ,Safety Information ,Adverse Drug Reactions ,Related Reactions ,Fetal Toxicity ,Full Prescribing Information ,Tokyo Based Astellas Pharma Inc ,Focus Area Approach ,Invasive Fungal Disease ,Astellas Pharma ,Astellas Pharma Us ,Nc ,